Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Microba Life Sciences Limited (MAP.AX)
Brisbane, QLD, AU
Microba Life Sciences Limited, established in Brisbane, Australia, in 2017, specializes in providing sophisticated microbiome testing and analytical services. These offerings reach clinicians, individual consumers, and research customers across key international markets, including Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, and the United States. The company delivers pathology, therapeutic, and diagnostic solutions deeply rooted in human gut microbiome science. Central to its operations is a comprehensive Databank, invaluable for unearthing therapeutic leads, fostering consumer health advancements, and identifying crucial diagnostic biomarkers. Moreover, Microba leverages a data-driven therapeutics platform to engineer innovative monoclonal microbial cell therapies aimed at treating inflammatory bowel disease, enhancing cancer immunotherapy, and managing autoimmune disorders.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.90% | -8.22% | -4.29% | -21.18% | -9.46% | -11.84% | -56.77% | -77.81% | -79.72% | -79.72% | -79.72% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Diagnostics & Research: +7.9%+29.6% ★ Q4'25: +123.7% (vs Q4'23)
-
EPS growth Medical - Diagnostics & Research: +30.8%+31.5% ★ Q4'25: +41.7% (vs Q4'23)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%-64.6% Q4'25: -80.5% (vs Q4'23)
-
EBIT margin Medical - Diagnostics & Research: +9.6%-95.4% Q4'25: -149.0% (vs Q4'23)
-
ROIC Medical - Diagnostics & Research: +5.2%-62.3% Q4'25: -191.7% (vs Q4'23)
-
Share dilution Medical - Diagnostics & Research: 0.0%+9.4% Q4'25: +57.5% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×-0.31× Q4'25: -0.10× (vs Q4'23)
| Metric |
Jun 2022 actual |
Jun 2023 actual |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 2 Rev. Ana. 1 EPS Ana. |
Jun 2027 2 Rev. Ana. 1 EPS Ana. |
Jun 2028 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
4.69M
est: 4.69M (0.0%)
|
5.42M
est: 5.40M (+0.4%)
|
12.09M
est: 9.94M (+21.6%)
|
15.67M
est: 15.70M (-0.2%)
|
16.10M
16.02M – 16.18M
+2.5% YoY
|
23.70M
22.61M – 24.79M
+47.2% YoY
|
29.45M
29.45M – 29.45M
+24.3% YoY
|
| EBITDA |
-9.86M
est: -4.38M (-125.1%)
|
-17.07M
est: -5.04M (-238.3%)
|
-17.10M
est: -9.29M (-84.2%)
|
-10.51M
est: -14.67M (+28.3%)
|
-15.04M
-15.11M – -14.97M
-2.5% YoY
|
-22.14M
-23.16M – -21.12M
-47.2% YoY
|
-27.51M
-27.51M – -27.51M
-24.3% YoY
|
| EBIT |
-11.45M
est: -4.65M (-146.5%)
|
-18.71M
est: -5.35M (-249.7%)
|
-19.97M
est: -9.85M (-102.8%)
|
-14.94M
est: -15.55M (+3.9%)
|
-15.95M
-16.03M – -15.87M
-2.5% YoY
|
-23.48M
-24.56M – -22.40M
-47.2% YoY
|
-29.18M
-29.18M – -29.17M
-24.3% YoY
|
| Net Income |
-11.47M
est: -20.52M (+44.1%)
|
-12.68M
est: -15.23M (+16.8%)
|
-19.94M
est: -19.94M (+0.0%)
|
-14.94M
est: -13.61M (-9.7%)
|
-11.88M
-12.18M – -11.58M
+12.7% YoY
|
-8.07M
-8.85M – -7.29M
+32.1% YoY
|
-6.05M
-6.28M – -5.82M
+25.0% YoY
|
| SGA |
3.14M
est: 4.09M (-23.2%)
|
4.12M
est: 4.70M (-12.4%)
|
12.97M
est: 8.66M (+49.7%)
|
17.61M
est: 13.68M (+28.8%)
|
14.03M
13.96M – 14.09M
+2.5% YoY
|
20.65M
19.70M – 21.60M
+47.2% YoY
|
25.66M
25.66M – 25.66M
+24.3% YoY
|
| EPS |
-0.04
est: -0.05 (+13.7%)
|
-0.04
est: -0.03 (-12.1%)
|
-0.05
est: -0.04 (-13.0%)
|
-0.03
est: -0.03 (-9.7%)
|
-0.03
-0.03 – -0.03
+12.7% YoY
|
-0.02
-0.02 – -0.02
+32.1% YoY
|
-0.01
-0.01 – -0.01
+25.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-26 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-25 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Luke Reid | Chief Executive Officer | 449.9K | — |
| James Heath | Chief Financial Officer & Company Secretary | 362.2K | male |
| Gene Tyson | Co-Founder & Non-Executive Director | 108.0K | — |
| Keith Byrne | Head of Test Operations | — | — |
| Lutz Krause | Chief Scientific Officer | — | — |
| Nicola Angel | Head of Laboratory Operations & Laboratory Director | — | — |
| Alaster Stockwell-Jones | Managing Director of UK | — | — |
| Philip Hugenholtz | Co-Founder & Chair of Scientific Advisory Board | — | — |
| David Wood | Chief Technology Officer | — | — |
| Eric Davies | Chief Revenue Officer | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for MAP.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
